单吸入器三联疗法治疗慢性阻塞性肺疾病的比较有效性与安全性:新使用者队列研究
该研究基于美国商业索赔数据,纳入2021年1月1日至2023年9月30日期间新启用布地奈德-格隆溴铵-福莫特罗或氟替卡松-乌美溴铵-维兰特罗的40岁及以上COPD患者,经1:1倾向评分匹配后各20388对。布地奈德-格隆溴铵-福莫特罗组首次中度或重度COPD急性加重的发生率较氟替卡松-乌美溴铵-维兰特罗组高9%(HR 1.09,95%CI 1.04-1.14),肺炎住院发生率两组相同(HR 1.00,95%CI 0.91-1.10)。
要点
- 布地奈德-格隆溴铵-福莫特罗组首次中度或重度COPD急性加重风险较氟替卡松-乌美溴铵-维兰特罗组高9%(HR 1.09)。
- 布地奈德-格隆溴铵-福莫特罗组首次中度COPD急性加重风险高7%(HR 1.07),首次重度COPD急性加重风险高29%(HR 1.29)。
- 两组首次肺炎住院发生率相同(HR 1.00,95%CI 0.91-1.10)。
核心结论
- 与氟替卡松-乌美溴铵-维兰特罗相比,布地奈德-格隆溴铵-福莫特罗未带来临床结局改善。
- 鉴于定量吸入器的额外气候影响,卫生系统可考虑采取措施在COPD患者中促进氟替卡松-乌美溴铵-维兰特罗而非布地奈德-格隆溴铵-福莫特罗的处方。
研究设计与样本
- 新使用者队列研究,使用美国纵向商业索赔数据。
- 纳入2021年1月1日至2023年9月30日期间新启用布地奈德-格隆溴铵-福莫特罗或氟替卡松-乌美溴铵-维兰特罗、诊断为COPD且年龄40岁及以上的患者。
- 采用1:1倾向评分匹配,协变量在队列进入前365天测量并纳入倾向评分。
- 研究队列包括20388对倾向评分匹配的新使用者。
- 使用Cox比例风险回归模型估计风险比和95%置信区间。
主要发现
- 布地奈德-格隆溴铵-福莫特罗组首次中度或重度COPD急性加重发生率较氟替卡松-乌美溴铵-维兰特罗组高9%(HR 1.09,95%CI 1.04-1.14;需伤害人数38)。
- 布地奈德-格隆溴铵-福莫特罗组与氟替卡松-乌美溴铵-维兰特罗组首次肺炎住院发生率相同(HR 1.00,95%CI 0.91-1.10)。
- 布地奈德-格隆溴铵-福莫特罗组首次中度COPD急性加重风险较氟替卡松-乌美溴铵-维兰特罗组高7%(HR 1.07,95%CI 1.02-1.12;需伤害人数54)。
- 布地奈德-格隆溴铵-福莫特罗组首次重度COPD急性加重风险较氟替卡松-乌美溴铵-维兰特罗组高29%(HR 1.29,95%CI 1.12-1.48;需伤害人数97)。
- 预设敏感性分析结果与主要分析相似。
临床怎么用
- 作者认为,鉴于定量吸入器的额外气候影响,卫生系统可考虑采取措施在COPD患者中促进氟替卡松-乌美溴铵-维兰特罗而非布地奈德-格隆溴铵-福莫特罗的处方。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler, in patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice. DESIGN: New user cohort study. SETTING: Longitudinal commercial US claims data. PARTICIPANTS: New initiators of budesonide-glycopyrrolate-formoterol or fluticasone-umeclidinium-vilanterol between 1 January 2021 and 30 September 2023 who had a diagnosis of COPD and were aged 40 years or older. MAIN OUTCOME MEASURES: In this 1:1 propensity score matched study, the main outcome measures were first moderate or severe COPD exacerbation (effectiveness) and first admission to hospital with pneumonia (safety) while on treatment. Potential confounders were measured in the 365 days before cohort entry and included in propensity scores. Hazard ratios and 95% confidence intervals (CIs) were estimated using a Cox proportional hazards regression model. RESULTS: The study cohort included 20 388 propensity score matched pairs of new users initiating single inhaler triple therapy. Patients who received budesonide-glycopyrrolate-formoterol had a 9% higher incidence of first moderate or severe COPD exacerbation (hazard ratio 1.09 (95% CI 1.04 to 1.14); number needed to harm 38) compared with patients receiving fluticasone-umeclidinium-vilanterol and an identical incidence of first admission to hospital with pneumonia (1.00 (0.91 to 1.10)). The hazard of first moderate COPD exacerbation was 7% higher (1.07 (1.02 to 1.12); number needed to harm 54) and the hazard of first severe COPD exacerbation 29% higher (1.29 (1.12 to 1.48); number needed to harm 97) among those receiving budesonide-glycopyrrolate-formoterol compared to fluticasone-umeclidinium-vilanterol. Prespecified sensitivity analyses yielded similar findings to the primary analysis. CONCLUSIONS: Budesonide-glycopyrrolate-formoterol was not associated with improved clinical outcomes compared with fluticasone-umeclidinium-vilanterol. Given the added climate impact of metered dose inhalers, health systems seeking to decrease use of these products may consider steps to promote further prescribing of fluticasone-umeclidinium-vilanterol compared with budesonide-glycopyrrolate-formoterol in people with COPD. STUDY REGISTRATION: Center for Open Science Real World Evidence Registry (https://osf.io/6gdyp/).
引用
- Feldman WB, Suissa S, Kesselheim AS, et al. Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study. BMJ. 2024. PMID: 39797646. doi:10.1136/bmj-2024-080409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。